Vendor Intelligence Report: Accelerate Labs

Published 3 Jul 2026. 28-page investigative report on who is behind Accelerate Labs: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Accelerate Labs is a product-specific vendor, not a catalog-wide bet. Across 20 Finnrick lab tests, the record is 12 pass / 8 fail — an overall pass rate of 60%. The better signal sits with GHK-Cu and Retatrutide, while BPC-157 and Melanotan II show repeat failures that should push buyers toward a different source or independent batch retesting.

The public business record is more complicated than the storefront suggests. The site presents a 2019 origin, but Florida filings, archive captures, and current-domain records start later; the former .com domain is now an Afternic listing while the .us domain remains canonical. That creates a practical authenticity problem for buyers following old links or coupon pages.

The operator and footprint trail is real but messy: an active Florida LLC, named founder/authorized-person records, a Miami PMB, Tampa and Ocala signals, Las Vegas addresses, and an open Nevada residential eviction docket naming the LLC. Accelerate Labs also sits in a higher-risk GLP-1 lane, with obfuscated product codes, preserved press reporting around injection guidance and no-prescription GLP-1 advertising, and COAs that address identity/purity but not sterility, endotoxin, heavy metals, or injection safety.

The resulting read is narrow: Accelerate Labs has identifiable paperwork and recognizable third-party purity testing, but its strongest and weakest products should not be treated as interchangeable. The full report is for buyers deciding which peptide, which batch evidence, and which authenticity checks matter before money leaves the card.

Inside the full report:

  • Per-product Finnrick pass/fail data, rating trajectories, and methodology-divergence charts for all 7 products
  • Florida SOS filings, operator/address analysis, and the Nevada eviction docket exhibit
  • Timeline comparing the 2019 history claim with LLC formation, archive captures, RDAP data, and Afternic domain status
  • GLP-1 intended-use analysis covering obfuscated product codes, Jezebel/WSJ evidence, and comparable FDA warning-letter logic
  • MZ Biolabs COA scope review versus missing sterility, endotoxin, heavy-metal, and injection-safety checks
  • Trustpilot, review-incentive, coupon-aggregator, and affiliate-scan findings with coverage limits

Risk assessment

  • Product-specific quality risk — BPC-157, Melanotan II, CJC-1295 — high: Finnrick shows BPC-157 0 pass / 3 fail, Melanotan II 0 pass / 2 fail, and CJC-1295 2 pass / 2 fail; use a better-testing source or independently retest the exact batch.
  • GLP-1 regulatory and intended-use risk — semaglutide, tirzepatide, retatrutide — high: 2023 Jezebel/WSJ injection and no-prescription advertising evidence plus current obfuscated GLP-1 codes undermine research-use-only positioning and raise continuity risk.
  • COA scope gap for injectable-use safety — medium: MZ Biolabs identity/purity COAs do not verify sterility, endotoxins, heavy metals, or injection safety for the vial in hand.
  • Operational opacity and facility-verification risk — medium: Miami PMB, Tampa/Ocala/Las Vegas address spread, Nevada residential eviction filing, and no disclosed dedicated facility limit storage/fulfillment confidence.
  • History-claim reliability risk — medium: Website claims a 2019 origin; supplied registry/domain records begin with 2021 Florida LLC filings and a 2023 .us domain registration.
  • Review-integrity risk — medium: Trustpilot is positive but a Reddit-reported 15% review discount and older complaints make reviews unsuitable as a standalone quality signal.
  • Brand-confusion and abandoned-domain risk — medium: Former accelerate-labs.com is for sale, while no official-channels list, authorized-reseller list, signed COA system, or anti-counterfeit check was found.